The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

Summary: Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochond...

Full description

Bibliographic Details
Main Authors: Luke D. Jasenosky, Cristhian Cadena, Chad E. Mire, Viktoriya Borisevich, Viraga Haridas, Shahin Ranjbar, Aya Nambu, Sina Bavari, Veronica Soloveva, Supriya Sadukhan, Gail H. Cassell, Thomas W. Geisbert, Sun Hur, Anne E. Goldfeld
Format: Article
Language:English
Published: Elsevier 2019-09-01
Series:iScience
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004219302287

Internet

http://www.sciencedirect.com/science/article/pii/S2589004219302287

Similar Items